Clinical Trials Browser

OTHER × ceralasertib × Clear all

NCT03462342 2026-03-17

CAPRI

Phase 2 Completed

High Grade Serous Carcinoma

NCT04090567 2026-03-05

Olaparib With Cediranib or AZD6738 for the Treatment of Advanced or Metastatic Germline BRCA Mutated Breast Cancer

Phase 2 Recruiting

Breast Neoplasms

NCT03801369 2026-02-25

AMTEC IIT: Phase 2 Multiarm Study in TNBC

Phase 2 Terminated

24 enrolled 16 charts

Triple Negative Breast Neoplasms

NCT04417062 2026-02-25

Olaparib With Ceralasertib in Recurrent Osteosarcoma

Phase 2 Active not recruiting

Osteosarcoma

NCT04065269 2026-02-20

ATARI

Phase 2 Active not recruiting

GynecologicSarcoma

Carcinosarcoma, Uterine Cervical Neoplasms, Endometrial Neoplasms, Carcinoma, Endometrioid

NCT03579316 2026-02-18

Adavosertib With or Without Olaparib in Treating Patients With Recurrent Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Phase 2 Active not recruiting

Fallopian Tube Neoplasms, Ovarian Neoplasms

NCT02813135 2026-01-16

ESMART

Phase 1/2 Recruiting

Neoplasms

NCT04699838 2026-01-02

Chemo-Immunotherapy Followed by Durvalumab and Ceralasertib in Treatment Naïve Patients With Extensive Stage Small Cell Lung Cancer

Phase 2 Recruiting

Extensive Stage Small Cell Lung Cancer

NCT04550104 2025-12-19

CONCORDE

Phase 1 Recruiting

Carcinoma, Non-Small-Cell Lung

NCT06680050 2025-12-18

AUSTRAL

Phase 2 Recruiting

Non Small Cell Lung Cancer NSCLC

NCT03770429 2025-09-29

AZD6738 for Patients With Progressive MDS or CMML

Phase 1 Active not recruiting

MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT05582538 2025-08-24

ATRiBRAVE

Phase 2 Recruiting

Triple Negative Breast Neoplasms

NCT03740893 2025-08-11

PHOENIX

Phase 2 Recruiting

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02223923 2025-08-01

Patriot

Phase 1 Unknown

Other solid neoplasm

Solid Tumour Refractory to Conventional Treatment

NCT02664935 2025-05-21

National Lung Matrix Trial: Multi-drug Phase II Trial in Non-Small Cell Lung Cancer

Phase 2 Active not recruiting

Adenocarcinoma, Carcinoma, Non-Small-Cell Lung, Carcinoma, Squamous Cell, Lung Neoplasms

NCT03787680 2025-03-28

Targeting Resistant Prostate Cancer With ATR and PARP Inhibition (TRAP Trial)

Phase 2 Active not recruiting

49 enrolled 11 charts

Prostatic Neoplasms

NCT03833440 2024-05-03

PIONeeR

Phase 2 Active not recruiting

Carcinoma, Non-Small-Cell Lung

NCT04298008 2024-04-19

AZD6738 Plus Durvalumab in Biliary Tract Cancer

Phase 2 Recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT04298021 2024-04-19

DDR-Umbrella Study of DDR Targeting Agents in Advanced Biliary Tract Cancer

Phase 2 Active not recruiting

Gastrointestinal

Bile Duct Neoplasms

NCT02576444 2022-12-28

OLAPCO

Phase 2 Terminated

67 enrolled 10 charts

Neoplasms

NCT02630199 2022-06-15

Study of AZD6738, DNA Damage Repair/Novel Anti-cancer Agent, in Combination With Paclitaxel, in Refractory Cancer

Phase 1 Completed

Neoplasms

NCT03780608 2022-06-15

This Study is a Phase II Study of AZD6738 in Combination With Durvalumab in Patients With Solid Tumor (Cohort A (N=30): GC Who Have Failed Secondary Chemotherapy Treatments Regimen; Cohort B (B=30): Melanoma Patients Who Have Failed to IO)

Phase 2 Unknown

Melanoma

NCT03669601 2021-06-04

ATRiUM

Phase 1 Unknown

Neoplasm Metastasis, Neoplasms

NCT03428607 2021-02-18

Study of AZD6738 and Olaparib Combination Therapy in Relapsed Small Cell Lung Cancer Patients [SUKSES-N2]

Phase 2 Completed

SCLC

NCT03182634 2019-01-22

plasmaMATCH

Phase 2 Unknown

Advanced Breast Cancer